Listed below are publications related to Visudyne® and ophthalmology. When you click on the link provided for each article, you will be leaving the QLT Inc. web site. Note that certain of the articles contain discussion about treatment regimes for Visudyne that are not discussed in the approved prescribing information. Click here for the approved prescribing information for Visudyne.
Combination Therapy
Controlled Studies
Uncontrolled and Other Studies
Visudyne® Treatment Guidelines
Review Papers
Other Papers
Combination Therapy
Navea A, Mataix J, Desco MC, Garcia-Pous M, Palacios E.
One-year follow-up of combined customized therapy. Photodynamic therapy and bevacizumab for exudative age-related macular degeneration.
Retina 2009; 29:13-19 (January 2009). Entrez PubMed
Kaiser PK.
Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration.
Curr Med Res Opin 2007;23 (3) : 477-87. Published online 25 January 2007; doi: 10.1185/030079907X167624 LibraPharm
Augustin AJ, Puls S, Offermann I.
Triple therapy for choroidal neovascularization due to age-related macular degeneration. Verteporfin PDT, bevacizumab, and dexamethasone.
Retina 2007; 27:133-140 (February 2007). Entrez PubMed
Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA, Tewari A.
Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
Retina 2006; 26:988-993 (November 2006). Entrez PubMed
Augustin A, Schmidt-Erfurth U.
Verteporfin therapy and triamcinolone acetonide: convergent modes of action for treatment of neovascular age-related macular degeneration.
Eur J Ophthalmol. 2006;16:824-834. Entrez Pubmed
Augustin A.J, Schmidt-Erfurth, U.
Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration.
Am J Ophthalmol. 2006;141:638-45 (April 2006). Entrez PubMed
Kaiser PK.
Verteporfin therapy in combination with triamcinolone: published studies investigating a potential synergistic effect.
Curr Med Res Opin. 2005;21:705-713 (May 2005). Entrez PubMed
 |
|
Controlled Studies
Boyer DS, Beer PM, Joffe L, Koester JM, Marx JL, Weisberger A, Yoser SL for the Adjunctive Diclofenac with Verteporfin (ADD-V) Study Group.
Effect of adjunctive diclofenac with verteporfin therapy to treat choroidal neovascularization due to age-related macular degeneration: phase II study.
Retina 2007;27(6):693-700. Entrez PubMed
Kaiser PK, Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group.
Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension. TAP Report No. 8.
Graefes Arch Clin Exp Ophthalmol. 2006;244(9):1132-42. [Epub 2006 Mar 15]. Entrez PubMed
Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group.
Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: four-year results of an open-label extension of 2 randomized clinical trials: TAP Report No. 7.
Arch Ophthalmol. 2005;123:1283-1285 (Sept. 2005). Entrez PubMed
Visudyne in Minimally Classic Choroidal Neovascularization Study Group.
Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.
Arch Ophthalmol. 2005;123:448-457 (April 2005). Entrez PubMed
VIP Report No. 5 Writing Committee.
Verteporfin in photodynamic therapy: Report No. 5.
[letter]. Ophthalmology. 2004;111:2144 (Nov. 2004). Entrez PubMed
Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group, and Verteporfin in Photodynamic Therapy (VIP) Study Group.
Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials - TAP and VIP Report No. 3.
Am J Ophthalmol. 2004; 137:683-696 (Apr. 2004) Entrez PubMed
Bressler SB, Pieramici DJ, Koester JM, Bressler NM for the TAP Study Group.
Natural history of minimally classic subfoveal choroidal neovascular lesions in the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation: outcomes potentially relevant to management - TAP Report No. 6.
Arch Ophthalmol. 2004;124:325-329 (Mar. 2004) Entrez PubMed
Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) Study Groups.
Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: TAP and VIP Study Report No.4.
Retina 2004;24:1-12 (Feb. 2004). Entrez PubMed
Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) Study Groups.
Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP Report No. 1.
Am J Ophthalmol, 2003;136;407-418 (Sept. 2003). Entrez PubMedM
Verteporfin in Photodynamic Therapy (VIP) Study Group.
Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial - VIP Report No. 3.
Ophthalmology. 2003;110-667-673 (Apr. 2003). Entrez PubMed
Improvement After Verteporfin Therapy Writing Committee for the TAP Study Group.
Improvement after verteporfin therapy
[letter]. Arch Ophthalmol. 2003;121:415-416 (Mar. 2003). Entrez PubMed
Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group.
Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes - TAP Report No. 3.
Arch Ophthalmol. 2002;120:1443-1454 (Nov. 2002). Entrez PubMed
Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group.
Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials - TAP Report No. 5.
Arch Ophthalmol. 2002;120:1307-1314 (Oct. 2002). Entrez PubMed
Rubin GS, Bressler NM, Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group.
Effects of verteporfin therapy on contrast sensitivity: results from the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation - TAP Report No. 4.
Retina. 2002;22:536-544 (Oct. 2002). Entrez PubMed
Ruiz-Oliva F, Cortes J.
Verteporfin in Photodynamic Therapy (VIP) Study Group
[letter]. Ophthalmol 2002;109:1043-1044 (June 2002). Entrez PubMed
Pozzo S, Parodi MB.
Prognosis for placebo-treated eyes in VIP Report 2
[letter]. Am J Ophthalmol, 2002;133:294-295 (Feb. 2002). Entrez PubMed
Jonas, JB.
Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration
[letter]. Am J Ophthalmol. 2002;133:857-859 (Feb. 2002). Entrez PubMed
Bressler NM.
Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photodynamic Therapy Report 2
[letter]. Am J Ophthalmol. 2002;133:168-169 (Jan. 2002). Entrez PubMed
Verteporfin in Photodynamic Therapy Study Group.
Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degernation: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photodynamic Therapy Report 2.
Am J Ophthalmol. 2001;131:541-560 (May 2001). Entrez PubMed
Verteporfin in Photodynamic Therapy (VIP) Study Group.
Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial - VIP Report No. 1.
Ophthalmology. 2001;108:841-852 (May 2001). Entrez PubMed
Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group.
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP Report 2.
Arch Ophthalmol. 2001;119:198-207 (Feb. 2001). Entrez PubMed
Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group.
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP Report 1.
Arch Ophthalmol, 1999;117:1329-1345 (Oct. 1999). Entrez PubMed
|
|
Uncontrolled and Other Studies
Rosenfeld PJ, Saperstein DA, Bressler NM et al, for the VOH Study Group.
Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled, open-label 2-year study.
Ophthalmology. 2004;111:1725-1733 (Sept. 2004). Entrez PubMed
The Japanese Age-Related Macular Degeneration Trial (JAT) Study Group.
Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
Am J Ophthalmol. 2003;136:1049-1061 (Dec. 2003) Entrez PubMed
Houle JM, Strong HA.
Duration of skin photosensitivity and incidence of photosensitivity reactions after administration of verteporfin.
Retina. 2002;22:691-697 (Dec. 2002). Entrez PubMed
Saperstein DA, Rosenfeld PJ, Bressler NM, et al. for the Verteporfin in Ocular histoplasmosis (VOH) Study Group.
Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series. Ophthalmology. 2002;109:1499-1505 (Aug. 2002). Entrez PubMed
Houle JM, Strong HA.
Clinical Pharmacokinetics of verteporfin.lJ Clin Pharmacol. 2002;42:547-557 (May 2002) Entrez PubMed
Sickenberg M, Schmidt-Erfurth U, Miller JW, et al.
A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angiod streaks, and idiopathic causes.
Arch Ophthalmol. 2000;118:327-336 (Mar. 2000). Entrez PubMed
Miller JW, Schmidt-Erfurth U, Sickenberg M, et al.
Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study.
Arch Ophthalmol. 1999;117:1161-1173 (Sept. 1999). Entrez PubMed
Schmidt-Erfurth U, Miller JW, Sickenberg M, et al.
Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.
Arch Ophthalmol. 1999;117:1177-1187 (Sept. 1999). Entrez PubMed
Visudyne Treatment Guidelines
Verteporfin Roundtable Participants.
Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update.
Retina. 2005;25:119-134 (Feb. 2005) Entrez PubMed
Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) Study Groups.
Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment - TAP and VIP Report No. 2.
Arch Ophthalmol. 2003;121:1253-1268 (Sept. 2003) Entrez PubMed
Verteporfin Roundtable 2000 and 2001 Participants, Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group principal investigators, Verteporfin in photodynamic therapy (VIP) study group principal investigators.
Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes: update.
Retina. 2002;22:6-18 (Feb. 2002). Entrez PubMed
Schmidt-Erfurth U, Miller J, Sickenberg M, et al.
Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples.
Graefes Arch Clin Exp Ophthalmol. 1998;236:365-374 (May 1998) Entrez PubMed
Review Papers
Virgili G, Do DV, Bressler NM, Menchini U.
New therapies for neovascular age-related macular degeneration: critical appraisal of new evidence.
Acta Ophthalmol Scand 2007; 85:6-20. Abstract
Miller DG, Singerman LJ.
Vision Loss in Younger Patients: A Review of Choroidal Neovascularization.
Optom Vis Sci. 2006 May;83(5):316-325.Optometry and Vision Science
Fletcher DC, Schuchard RA.
Visual function in patients with choroidal neovascularization resulting from age-related macular degeneration: the importance of looking beyong visual acuity.
Optom Vis Sci. 2006;83(3):178-189 (March 2006). Entrez PubMed
Pauleikhoff D.
Neovasucular age-related macular degeneration: Natural History and Treatment Outcomes.
Retina. 2005;25 (8):1065-1084 (Dec. 2005). Entrez PubMed
Mones, J, Rubin GS.
Contrast sensitivity as an outcome measure in patients with subfoveal choroidal neovascularization due to age-related macular degeneration.
Eye. 2005;19:1142=1150 (Nov. 2005). Entrez PubMed
Slakter JS, Stur M.
Quality of life in patients with age-related macular degeneration: impact of the condition and benefits of treatment.
Surv Ophthalmol. 2005;50:263-273 (May-June 2005). Entrez PubMed
Harvey PT.
Common eye diseases of elderly people: identifying and treating causes of vision loss.
Gerontology. 2003;49:1-11 (Jan-Feb. 2003). Entrez PubMed
Rosenthal B, Thompson R.
Awareness of age-related macular degeneration in adults: the results of large-scale international survey.
Optometry. 2003;74:16-24 (jan. 2003). Entrez PubMed
Keam SJ, Scott LJ, Curran MP.
Verteporfin: a review of its use in the management of subfoveal choroidal neovascularization.
Drugs. 2003;63(22):2521-54. Review. Entrez PubMed
Lanzetta P.
New treatments for CNV secondary to AMD: what evidence exists to support a treatment recommendation?
Graefes Arch Clin Exp Ophthalmol. 2002;240:885-888 (Nov. 2002). Entrez PubMed
Other Papers
Zawinka C, Ergun E, Stur M.
Prevalence of patients presenting with neovascular age-related macular degeneration in an urban population.
Retina. 2005;25:324-331 (April-May 2005). Entrez PubMed
Dougherty TJ, Levy JG.
Photodynamic therapy (PDT) and clinical applications.
In: Vo-Dinh T, ed. Biomedical Photonics Handbook. Boca Raton, FL: CRC Press; 2003:38-1-38-6. SPIE Bookstore
Sawa M, Ohji M, Gomi F, Kusaka S, Tano Y, Bressler NM.
Apparent disappearance of choroidal neovascularization after initial photodynamic therapy with verteporfin.
Arch Ophthalmol. 2002:120:1588-1590 (Nov. 2002). Entrez PubMed
North JR.
Liposomes - the Visudyne story: progress in photodynamic therapy for age-related macular degeneration.
Prog Drug Deliv Sys VIII. 1999;8:73-81.
|
